These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 28991823)

  • 41. Protein C: a potential biomarker in severe sepsis and a possible tool for monitoring treatment with drotrecogin alfa (activated).
    Shorr AF; Nelson DR; Wyncoll DL; Reinhart K; Brunkhorst F; Vail GM; Janes J
    Crit Care; 2008; 12(2):R45. PubMed ID: 18394162
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effect of the immunomodulating agent, pentoxifylline, in the treatment of sepsis in prematurely delivered infants: a placebo-controlled, double-blind trial.
    Lauterbach R; Pawlik D; Kowalczyk D; Ksycínski W; Helwich E; Zembala M
    Crit Care Med; 1999 Apr; 27(4):807-14. PubMed ID: 10321674
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Influence of enrollment sequence effect on observed outcomes in the ADDRESS and PROWESS studies of drotrecogin alfa (activated) in patients with severe sepsis.
    Laterre PF; Macias WL; Janes J; Williams MD; Nelson DR; Girbes AR; Dhainaut JF; Abraham E
    Crit Care; 2008; 12(5):R117. PubMed ID: 18786266
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A multicenter randomized trial of atorvastatin therapy in intensive care patients with severe sepsis.
    Kruger P; Bailey M; Bellomo R; Cooper DJ; Harward M; Higgins A; Howe B; Jones D; Joyce C; Kostner K; McNeil J; Nichol A; Roberts MS; Syres G; Venkatesh B;
    Am J Respir Crit Care Med; 2013 Apr; 187(7):743-50. PubMed ID: 23348980
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Drotrecogin alfa (activated): a pharmacoeconomic review of its use in severe sepsis.
    Frampton JE; Foster RH
    Pharmacoeconomics; 2004; 22(7):445-76. PubMed ID: 15137883
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Talactoferrin in Severe Sepsis: Results From the Phase II/III Oral tAlactoferrin in Severe sepsIS Trial.
    Vincent JL; Marshall JC; Dellinger RP; Simonson SG; Guntupalli K; Levy MM; Singer M; Malik R;
    Crit Care Med; 2015 Sep; 43(9):1832-8. PubMed ID: 26010687
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The systemic mediator-associated response test identifies patients in failed sepsis clinical trials among whom novel drugs reduce mortality.
    Slotman GJ
    J Trauma; 2011 Nov; 71(5):1406-14. PubMed ID: 21537209
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Human recombinant activated protein C for severe sepsis.
    Martí-Carvajal A; Salanti G; Cardona AF
    Cochrane Database Syst Rev; 2008 Jan; (1):CD004388. PubMed ID: 18254048
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Changes in plasma interleukin-33 concentration in sepsis and its correlation with seriousness of sepsis].
    Chang D; Jia J; Zang B
    Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2015 Feb; 27(2):138-42. PubMed ID: 25665614
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Human recombinant activated protein C for severe sepsis.
    Martí-Carvajal AJ; Solà I; Lathyris D; Cardona AF
    Cochrane Database Syst Rev; 2012 Mar; (3):CD004388. PubMed ID: 22419295
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effect of Ganciclovir on IL-6 Levels Among Cytomegalovirus-Seropositive Adults With Critical Illness: A Randomized Clinical Trial.
    Limaye AP; Stapleton RD; Peng L; Gunn SR; Kimball LE; Hyzy R; Exline MC; Files DC; Morris PE; Frankel SK; Mikkelsen ME; Hite D; Enfield KB; Steingrub J; O'Brien J; Parsons PE; Cuschieri J; Wunderink RG; Hotchkin DL; Chen YQ; Rubenfeld GD; Boeckh M
    JAMA; 2017 Aug; 318(8):731-740. PubMed ID: 28829877
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pancreatic stone protein as an early biomarker predicting mortality in a prospective cohort of patients with sepsis requiring ICU management.
    Que YA; Delodder F; Guessous I; Graf R; Bain M; Calandra T; Liaudet L; Eggimann P
    Crit Care; 2012 Jul; 16(4):R114. PubMed ID: 22748193
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Influence of severity of illness on the effects of eritoran tetrasodium (E5564) and on other therapies for severe sepsis.
    Kalil AC; LaRosa SP; Gogate J; Lynn M; Opal SM;
    Shock; 2011 Oct; 36(4):327-31. PubMed ID: 21701421
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cost-effectiveness of recombinant human activated protein C and the influence of severity of illness in the treatment of patients with severe sepsis.
    Fowler RA; Hill-Popper M; Stasinos J; Petrou C; Sanders GD; Garber AM
    J Crit Care; 2003 Sep; 18(3):181-91; discussion 191-4. PubMed ID: 14595571
    [TBL] [Abstract][Full Text] [Related]  

  • 55. INTERSEPT: an international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis. International Sepsis Trial Study Group.
    Cohen J; Carlet J
    Crit Care Med; 1996 Sep; 24(9):1431-40. PubMed ID: 8797612
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Intravenous immunoglobulin for treating sepsis, severe sepsis and septic shock.
    Alejandria MM; Lansang MA; Dans LF; Mantaring JB
    Cochrane Database Syst Rev; 2013 Sep; 2013(9):CD001090. PubMed ID: 24043371
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK 195F, in patients with sepsis and septic shock: a multicenter, randomized, placebo-controlled, dose-ranging study.
    Reinhart K; Wiegand-Löhnert C; Grimminger F; Kaul M; Withington S; Treacher D; Eckart J; Willatts S; Bouza C; Krausch D; Stockenhuber F; Eiselstein J; Daum L; Kempeni J
    Crit Care Med; 1996 May; 24(5):733-42. PubMed ID: 8706447
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effect of pentoxifylline in severe sepsis: results of a randomized, double-blind, placebo-controlled study.
    Staubach KH; Schröder J; Stüber F; Gehrke K; Traumann E; Zabel P
    Arch Surg; 1998 Jan; 133(1):94-100. PubMed ID: 9438767
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Evaluation of Effect of Probiotics on Cytokine Levels in Critically Ill Children With Severe Sepsis: A Double-Blind, Placebo-Controlled Trial.
    Angurana SK; Bansal A; Singhi S; Aggarwal R; Jayashree M; Salaria M; Mangat NK
    Crit Care Med; 2018 Oct; 46(10):1656-1664. PubMed ID: 29957709
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Drotrecogin alfa: a second look. More clinical trials in severe sepsis: mostly negative results.
    Prescrire Int; 2007 Feb; 16(87):7-9. PubMed ID: 17323514
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.